BioLight Announced that the Subsidiary IOPtima Received Regulatory Approval for the Marketing and Sale of the IOPtiMate™ System in China

BioLight announces that the subsidiary IOPtima (87.17%) notified it that the China Food and Drug Administration (the CFDA) approved the marketing and sale of the IOPtiMate™ system in China.

Link to comlete article

Link to Newsroom

Comments are closed